Somewhat Positive Press Coverage Somewhat Unlikely to Affect Clearside Biomedical (CLSD) Stock Price

News headlines about Clearside Biomedical (NASDAQ:CLSD) have trended somewhat positive on Thursday, Accern reports. Accern scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Clearside Biomedical earned a news impact score of 0.11 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 44.4765902356554 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of Clearside Biomedical (CLSD) opened at $6.32 on Thursday. Clearside Biomedical has a fifty-two week low of $5.44 and a fifty-two week high of $10.36. The stock has a market capitalization of $161.18 and a price-to-earnings ratio of -3.29. The company has a current ratio of 4.57, a quick ratio of 4.57 and a debt-to-equity ratio of 0.15.

Clearside Biomedical (NASDAQ:CLSD) last issued its earnings results on Wednesday, November 8th. The company reported ($0.72) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.17). The firm had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.01 million. Clearside Biomedical had a negative net margin of 11,829.68% and a negative return on equity of 161.25%. research analysts expect that Clearside Biomedical will post -2.37 EPS for the current fiscal year.

CLSD has been the subject of several research analyst reports. Zacks Investment Research downgraded Clearside Biomedical from a “hold” rating to a “sell” rating in a research note on Monday, November 13th. Cowen reissued a “buy” rating on shares of Clearside Biomedical in a research report on Wednesday, October 25th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $18.33.

In other Clearside Biomedical news, insider Daniel H. White sold 8,000 shares of the business’s stock in a transaction dated Thursday, October 19th. The stock was sold at an average price of $7.82, for a total transaction of $62,560.00. Following the transaction, the insider now owns 477,935 shares in the company, valued at $3,737,451.70. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Clay Thorp sold 35,000 shares of Clearside Biomedical stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $7.00, for a total value of $245,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 78,000 shares of company stock worth $539,060. 20.90% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at

About Clearside Biomedical

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

Insider Buying and Selling by Quarter for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with's FREE daily email newsletter.

Leave a Reply